22 Jul 2018 | 12:24 PM
 

Cadila Healthcare Ltd. Share Price Live (BSE)
0

BSE Code: 532321 | NSE Symbol: CADILAHC
346.00
2.70
(0.79 %)
20 Jul 2018 | 03:56 PM
Change company
  • Open (Rs)
    343.00
  • Prev. close (Rs.)
    343.30
  • High (Rs.)
    350.60
  • Low (Rs.)
    333.35
  • 52W H (Rs.)
    554.21
  • 52W L (Rs.)
    341.65
  • Volume
    252933
  • MCap (Rs in Cr.)
    35,421.51

Stock Market News

Cadila Healthcare Ltd. Stock News

Company Name
From Date
To Date
  Cadila Healthcare Ltd. | 20 Jul 2018 | 13:06:00
Zydus Cadila has received final approval from the US health regulator to market Spironolactone tablets used to treat high blood pressure and heart failure...
  Cadila Healthcare Ltd. | 19 Jul 2018 | 11:32:00
Cadila has received final approval from the US health regulator for Piroxicam Capsules used for treatment of osteoarthritis and rheumatoid arthritis reported PTI...
  Cadila Healthcare Ltd. | 19 Jul 2018 | 11:08:00
Zydus Cadila has said that it has received the final approval from the USFDA to market Piroxicam Capsules USP (US RLD - Feldene Capsules) in strengths of 10 mg and 20 mg...
  Cadila Healthcare Ltd. | 18 Jul 2018 | 10:11:00
Zydus Cadila has said that it has received four consecutive final approvals from the USFDA to market Olanzapine Tablets USP Glipizide Extended-Release Tablets Voriconazole for Injection and Fluocinonide Topical Solution USP...
  Cadila Healthcare Ltd. | 12 Jul 2018 | 15:27:00
Cadila Healthcare said that the manufacturing facility of Zydus Hopsira Oncology a 50:50 joint venture company between Zydus Cadila and Hospira Inc...
  Cadila Healthcare Ltd. | 12 Jul 2018 | 12:03:00
Zydus Cadila has received final approval from the US health regulator to market Zolmitriptan tablets used to relieve headache pain and other migraine symptom...
  Cadila Healthcare Ltd. | 05 Jul 2018 | 14:34:00
Drug firm Zydus Cadila today said it has inked an agreement with Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology to identify new drug candidates for treatment of drug resistant infections...
  Cadila Healthcare Ltd. | 02 Jul 2018 | 09:24:00
Zydus Cadila has said that it has received the final approval from the USFDA to market Triamterene and Hydrochlorothiazide Tablets USP in strengths of 37.5 mg/25 mg and 75 mg/SO mg.

It is used for the treatment of high blood pressure...